Please login to the form below

secukinumab

This page shows the latest secukinumab news and features for those working in and with pharma, biotech and healthcare.

from biosimilars and newer drugs such as Novartis’fast-growing IL-17 inhibitor Cosentyx (secukinumab).

Novartis follows Pfizer and freezes US prices this year

Novartis’decision to keep pricing steady has been helped by a rosy set of second-quarter results, with recent launches Cosentyx (secukinumab) for psoriasis and heart failure therapy Entresto (sacubitril and
GSK sells eczema and psoriasis drug to Dermavant for £250m

In the case of psoriasis, that includes not only new therapies such as Novartis’IL-17 inhibitor Cosentyx (secukinumab) and Johnson &Johnson’s IL-23/IL-12 inhibitor Tremfya (guselkumab), but
UK, Germany back routine use of J&J’s Tremfya

psoriasis therapies such as Novartis’fast-growing IL-17 inhibitor Cosentyx (secukinumab), which EvaluatePharma expects to become a $4.6bn product by 2022.
Sun Pharma passes milestone with novel psoriasis drug approval

IL-23-selective follow-up Tremfya (guselkumab) as well as three IL-17 inhibitors - Novartis’ Cosentyx (secukinumab), Eli Lilly’s Taltz (ixekizumab) and Valeant Pharma’s Siliq (brodalumab).
AbbVie reports more solid data for would-be psoriasis blockbuster

Its profile could also help it make headway against other new psoriasis drugs, including IL-17 inhibitors such as Novartis’fast-growing Cosentyx (secukinumab) as well as Eli Lilly’s Taltz

More from news
Approximately 16 fully matching, plus 60 partially matching documents found.

AIMM Therapeutics appoints former Novartis VP Jan de Vries as CEO

multiple sclerosis and secukinumab for several inflammatory conditions.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Senior Medical Writer, MedComms Agency: £40 - 55, 000 according to skills and experience benefits

Integrated Brand/ Digital Senior Account Director, London: Excellent package

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Leadership opportunity, Pricing & Market Access, UK, Substan...: Substantial six figure package

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Senior Medical Writer, Principal Medical Writer, Scientific Dire...: £40000 - £75000 Bonus Benefits

Add my company

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government: GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....